More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$274145838
EPS
-0.21
P/E ratio
--
Price to sales
0.91
Dividend yield
--
Beta
0.81267
Previous close
$24.80
Today's open
$24.69
Day's range
$24.19 - $25.50
52 week range
$11.16 - $25.50
show more
CEO
Paul S. Walker
Employees
1084
Headquarters
Draper, UT
Exchange
New York Stock Exchange
Shares outstanding
11272444
Issue type
Common Stock
Consumer Staples
Education
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.
Business Wire • May 27, 2026

80% of Individual Contributors Say Their Manager's Approach to AI is Hands-Off, FranklinCovey Research Finds
SALT LAKE CITY--(BUSINESS WIRE)-- #AI--As organizations race to capture the benefits of artificial intelligence, research from FranklinCovey Institute reveals a critical obstacle: most employees feel they are navigating AI alone, without meaningful support or guidance. Eighty percent of individual contributors describe their manager's approach to AI as “hands-off,” which underscores a widening gap between AI's potential and how it's actually used at work. FranklinCovey's 2025 AI General Attitudes Sur.
Business Wire • May 21, 2026

Diploma H1 Earnings Call Highlights
Diploma LON: DPLM reported what management described as a “very strong” first half for the six months ended March 31, 2026, with double-digit organic growth, higher margins and upgraded full-year expectations.
MarketBeat • May 19, 2026

Firm Capital Mortgage Investment Corporation Announces Q1/2026 Results and Declares Monthly Cash Dividends for July, August and September 2026
TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX FC, FC.DB. K, FC.DB. L and FC.DB.M) today released its financial statements for the three months ended March 31, 2026.
GlobeNewsWire • May 5, 2026

Top 2 Industrials Stocks You May Want To Dump In Q2
As of April 2, 2026, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Benzinga • Apr 2, 2026

Franklin Covey Co. (FC) Q2 2026 Earnings Call Transcript
Franklin Covey Co. (FC) Q2 2026 Earnings Call Transcript
Seeking Alpha • Apr 2, 2026

Franklin Covey Reports Second Quarter Fiscal 2026 Financial Results
SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner, gives strategy the human edge. We help clients achieve breakthrough results and transform how they execute strategy at scale. Today, the Company announced its financial results for the second quarter of fiscal 2026, which ended on February 28, 2026. Second Quarter Fiscal 2026 Financial Overview The Company's consolidated revenue for Q2 FY2026 was $59.6 million, which was f.
Business Wire • Apr 1, 2026

Franklin Covey (FC) Reports Q2 Loss, Tops Revenue Estimates
Franklin Covey (FC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.08 per share a year ago.
Zacks Investment Research • Apr 1, 2026

FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction
SALT LAKE CITY--(BUSINESS WIRE)-- #CNO--FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction.
Business Wire • Mar 27, 2026

Franklin Covey: What I'm Looking For In Q2 Earnings
Despite the recent fundamental declines, I believe Franklin Covey remains structurally attractive with material untapped TAM despite that should prevail past recent weakness. I'll be watching for continued sales momentum as reflected in Q1, continued new logo growth generation, SG&A levels, guidance, and capital allocation (particularly share repurchases). Despite the price run-up in recent weeks, I still believe FC offers an attractive IRR.
Seeking Alpha • Mar 26, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Franklin Covey Company commission-free¹. Build wealth for the long term using automated trading and transfers.